Humacyte shares are trading lower by 29% during Wednesday's session. The company priced a $50 million public offering.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

Humacyte shares are tumbling in Tuesday's after-hours session after the company announced a proposed public offering.

Humacyte (NASDAQ:HUMA) has announced the pricing of an underwritten public offering of 25 million shares of its common stock for total gross proceeds of approximately $50 million. The underwriters are ...

Stock futures were looking for direction in the premarket hours of Wednesday as investors awaited a series of key economic reports. Here are some of Wednesday's biggest stock movers: Biggest stock ...

Humacyte's stock struggles despite FDA approval for Symvess, with financial concerns and slow adoption impacting future ...

(Nasdaq: HUMA), a commercial-stage biotechnology platform ... underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share.

Humacyte, Inc. (HUMA) ended the recent trading session at $3.32, demonstrating no swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.77%.

Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...

$HUMA insiders have traded $HUMA stock on the open market 19 times in the past 6 months. Of those trades, 5 have been purchases and 14 have been sales.